• Publications
  • Influence

  • Lisa Pleyer, Hartmut Döhner, +24 authors Richard Greil
  • Medicine
  • International journal of molecular sciences
  • 2017 (First Publication: 1 February 2017)
  • We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC)Expand
  • Lisa Pleyer, Sonja Burgstaller, +19 authors Richard Greil
  • Medicine
  • Journal of Hematology & Oncology
  • 2016 (First Publication: 16 April 2016)
  • BackgroundThe MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to beExpand
  • Lisa Pleyer, Sonja Burgstaller, +19 authors Richard Greil
  • Medicine
  • 2015 (First Publication: 3 December 2015)
  • Background In the Phase III trial (AML-001; [NCT01074047][1]) that assessed azacitidine (AZA) vs conventional care regimens (CCR; intensive chemotherapy, low-dose cytarabine or best supportive careExpand
  • Anna Mies, Ekaterina V. Bulycheva, Inga Mandac Rogulj, Lorenz Christian Hofbauer, Uwe Platzbecker
  • Biology, Medicine
  • Current pharmaceutical design
  • 2016 (First Publication: 1 May 2016)
  • Hematopoietic and mesenchymal stem and progenitor cells are organized in the osteo-hematopoietic niche, a complex microenvironment ensuring self-renewal and differentiation. Perturbations of theExpand
    The occurrence of B-cell chronic lymphocytic leukemia (B-CLL) and another B-cell neoplasm in the same patient is a rare event and is mostly described in the literature as single case reports. In mostExpand